← Leaderboards
Jordan Bradley King
Kaiser Foundation Research Institute
$4,399,984
Attributed
$4,399,984
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $672K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,101,192 · 1
AHRQ$1,298,792 · 1
By mechanism
R01$3,101,192 · 1
R18$1,298,792 · 1
Top collaborators
No co-investigators on record.
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Lynn Larson Debar$40,780,655
- Richard W Grant$15,968,167
- Adrianne C Feldstein$4,179,305
- Gregory N Clarke$28,754,200
- Jason M Glanz$7,837,583
Others in their field
Other Emerging Leaders on “Cross-Over Trials”
- Xinhua Li · Nano Terra, Inc.$23,903,965
- Yunda Huang · Fred Hutchinson Cancer Center$11,638,099
- Heidi Irma Jacobs · Massachusetts General Hospital$4,558,716
- Nabil Alshurafa · Northwestern University At Chicago$3,523,864
- Ying-Hui Chou · University Of Arizona$3,468,515
- Ari Moskowitz · Beth Israel Deaconess Medical Center$3,296,402
Research focus
Cross-Over TrialsAdherenceAffectAdoptionAdultBehaviorBeliefBiological MarkersCardiovascular Disorder PreventionAtherosclerosisCardiovascular Risk FactorCaringCessation Of LifeCholesterolClassificationClinical PracticeClinical PsychologyCognitiveCollectionCompare EffectivenessComputer SoftwareCardiovascular Disorder RiskCostDiagnosis
Grant awards (9)
Development, testing, and implementation of virtual statin associated muscle symptom (SAMS) management$637,293
R01 · FY2025 · HL · contact PI
Development, testing, and implementation of virtual statin associated muscle symptom (SAMS) management$577,783
R01 · FY2024 · HL · contact PI
Development, testing, and implementation of virtual statin associated muscle symptom (SAMS) management$598,919
R01 · FY2023 · HL · contact PI
Development, testing, and implementation of virtual statin associated muscle symptom (SAMS) management$615,151
R01 · FY2022 · HL · contact PI
Development, testing, and implementation of virtual statin associated muscle symptom (SAMS) management$672,046
R01 · FY2021 · HL · contact PI
Management of Direct Oral Anticoagulants to Lower Adverse Events in Atrial Fibrillation (MODL-AF)$419,195
R18 · FY2020 · HS · contact PI
Management of Direct Oral Anticoagulants to Lower Adverse Events in Atrial Fibrillation (MODL-AF)$419,031
R18 · FY2019 · HS · contact PI
Management of Direct Oral Anticoagulants to Lower Adverse Events in Atrial Fibrillation (MODL-AF)$459,869
R18 · FY2018 · HS · contact PI
Management of Direct Oral Anticoagulants to Lower Adverse Events in Atrial Fibrillation (MODL-AF)$697
R18 · FY2018 · HS · contact PI